Literature DB >> 17142309

Novel patterns of genome rearrangement and their association with survival in breast cancer.

James Hicks1, Alexander Krasnitz, B Lakshmi, Nicholas E Navin, Michael Riggs, Evan Leibu, Diane Esposito, Joan Alexander, Jen Troge, Vladimir Grubor, Seungtai Yoon, Michael Wigler, Kenny Ye, Anne-Lise Børresen-Dale, Bjørn Naume, Ellen Schlicting, Larry Norton, Torsten Hägerström, Lambert Skoog, Gert Auer, Susanne Månér, Pär Lundin, Anders Zetterberg.   

Abstract

Representational Oligonucleotide Microarray Analysis (ROMA) detects genomic amplifications and deletions with boundaries defined at a resolution of approximately 50 kb. We have used this technique to examine 243 breast tumors from two separate studies for which detailed clinical data were available. The very high resolution of this technology has enabled us to identify three characteristic patterns of genomic copy number variation in diploid tumors and to measure correlations with patient survival. One of these patterns is characterized by multiple closely spaced amplicons, or "firestorms," limited to single chromosome arms. These multiple amplifications are highly correlated with aggressive disease and poor survival even when the rest of the genome is relatively quiet. Analysis of a selected subset of clinical material suggests that a simple genomic calculation, based on the number and proximity of genomic alterations, correlates with life-table estimates of the probability of overall survival in patients with primary breast cancer. Based on this sample, we generate the working hypothesis that copy number profiling might provide information useful in making clinical decisions, especially regarding the use or not of systemic therapies (hormonal therapy, chemotherapy), in the management of operable primary breast cancer with ostensibly good prognosis, for example, small, node-negative, hormone-receptor-positive diploid cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142309      PMCID: PMC1665631          DOI: 10.1101/gr.5460106

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  48 in total

1.  PROBER: oligonucleotide FISH probe design software.

Authors:  Nicholas Navin; Vladimir Grubor; Jim Hicks; Evan Leibu; Elizabeth Thomas; Jennifer Troge; Michael Riggs; Pär Lundin; Susanne Månér; Jonathan Sebat; Anders Zetterberg; Michael Wigler
Journal:  Bioinformatics       Date:  2006-06-01       Impact factor: 6.937

2.  The Stability of Broken Ends of Chromosomes in Zea Mays.

Authors:  B McClintock
Journal:  Genetics       Date:  1941-03       Impact factor: 4.562

Review 3.  HER2 as a prognostic factor in breast cancer.

Authors:  S Ménard; S Fortis; F Castiglioni; R Agresti; A Balsari
Journal:  Oncology       Date:  2001       Impact factor: 2.935

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.

Authors:  Zahra Madjd; Ian Spendlove; Sarah E Pinder; Ian O Ellis; Lindy G Durrant
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

Review 6.  The genetics and genomics of cancer.

Authors:  Allan Balmain; Joe Gray; Bruce Ponder
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

7.  retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.

Authors:  Ann S Knoop; Helle Knudsen; Eva Balslev; Birgitte B Rasmussen; Jens Overgaard; Kirsten V Nielsen; Andreas Schonau; Katrín Gunnarsdóttir; Karen E Olsen; Henning Mouridsen; Bent Ejlertsen
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

8.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Authors:  G Wiedswang; E Borgen; R Kåresen; G Kvalheim; J M Nesland; H Qvist; E Schlichting; T Sauer; J Janbu; T Harbitz; B Naume
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

Review 9.  Cyclin D1, EMS1 and 11q13 amplification in breast cancer.

Authors:  Christopher J Ormandy; Elizabeth A Musgrove; Rina Hui; Roger J Daly; Robert L Sutherland
Journal:  Breast Cancer Res Treat       Date:  2003-04       Impact factor: 4.872

10.  Improved grading of breast adenocarcinomas based on genomic instability.

Authors:  Ulrike Kronenwett; Sören Huwendiek; Carin Ostring; Neil Portwood; Uwe J Roblick; Yudi Pawitan; Ayodele Alaiya; Roland Sennerstam; Anders Zetterberg; Gert Auer
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

View more
  138 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.

Authors:  Reena Shakya; Latarsha J Reid; Colleen R Reczek; Francesca Cole; Dieter Egli; Chyuan-Sheng Lin; Dirk G deRooij; Steffen Hirsch; Kandasamy Ravi; James B Hicks; Matthias Szabolcs; Maria Jasin; Richard Baer; Thomas Ludwig
Journal:  Science       Date:  2011-10-28       Impact factor: 47.728

3.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient.

Authors:  William Lee; Zhaoshi Jiang; Jinfeng Liu; Peter M Haverty; Yinghui Guan; Jeremy Stinson; Peng Yue; Yan Zhang; Krishna P Pant; Deepali Bhatt; Connie Ha; Stephanie Johnson; Michael I Kennemer; Sankar Mohan; Igor Nazarenko; Colin Watanabe; Andrew B Sparks; David S Shames; Robert Gentleman; Frederic J de Sauvage; Howard Stern; Ajay Pandita; Dennis G Ballinger; Radoje Drmanac; Zora Modrusan; Somasekar Seshagiri; Zemin Zhang
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

4.  MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer.

Authors:  Kim J Png; Mitsukuni Yoshida; Xiang H-F Zhang; Weiping Shu; Hyeseung Lee; Andreas Rimner; Timothy A Chan; Elizabeth Comen; Viktor P Andrade; Seok Won Kim; Tari A King; Clifford A Hudis; Larry Norton; James Hicks; Joan Massagué; Sohail F Tavazoie
Journal:  Genes Dev       Date:  2011-02-01       Impact factor: 11.361

5.  Assessment of palindromes as platforms for DNA amplification in breast cancer.

Authors:  Jamie Guenthoer; Scott J Diede; Hisashi Tanaka; Xiaoyu Chai; Li Hsu; Stephen J Tapscott; Peggy L Porter
Journal:  Genome Res       Date:  2011-07-13       Impact factor: 9.043

6.  A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome.

Authors:  Oliver A Hampton; Petra Den Hollander; Christopher A Miller; David A Delgado; Jian Li; Cristian Coarfa; Ronald A Harris; Stephen Richards; Steven E Scherer; Donna M Muzny; Richard A Gibbs; Adrian V Lee; Aleksandar Milosavljevic
Journal:  Genome Res       Date:  2008-12-03       Impact factor: 9.043

7.  Target inference from collections of genomic intervals.

Authors:  Alexander Krasnitz; Guoli Sun; Peter Andrews; Michael Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

8.  Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.

Authors:  Philip Hahnfeldt; Lynn Hlatky; Giannoula Lakka Klement
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

9.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

10.  Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.

Authors:  Andrzej B Popławski; Michał Jankowski; Stephen W Erickson; Teresita Díaz de Ståhl; E Christopher Partridge; Chiquito Crasto; Jingyu Guo; John Gibson; Uwe Menzel; Carl Eg Bruder; Aneta Kaczmarczyk; Magdalena Benetkiewicz; Robin Andersson; Johanna Sandgren; Barbara Zegarska; Dariusz Bała; Ewa Srutek; David B Allison; Arkadiusz Piotrowski; Wojciech Zegarski; Jan P Dumanski
Journal:  Eur J Hum Genet       Date:  2010-01-06       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.